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1I .  INTRODUCTION
Research on the re la tionsh ip  between the ro le  of stress and
blood catecholamine levels began in the early  60 's. Studies since
that time have shown that both physical and psychological 
stressors can cause an increase in the c ircu la t in g  levels of 
catecholamines. Epinephrine and norepinephrine are the 
catecholamines most implicated as being affected by stress. The 
resu lts  have not been clear as to whether the two catecholamines 
respond d i f fe re n t ia l ly  to physical and psychological stress. 
Epinephrine secretion appears to increase in response to anxiety 
while norepinephrine may be related to aggression.
Nicotine is a chemical stressor which causes an increase in
epinephrine secretion and has produced adrenal hypertrophy in 
exposed animals. Nicotine is also responsible fo r  the 
s ig n i f ic a n t ly  lower ascorbic acid levels in smokers as compared to 
nonsmokers. L-ascorbic acid might be involved in the regulation 
of normal or increased levels of tissue catecholamines by i t s  ro le  
as a cofactor in enzymic biosynthesis (1-3). Other evidence 
points to L-ascorbic acid as a regulatory agent against both 
inactiva tion  and excessive build-up of c ircu la t in g  catecholamines. 
I t  might act as an in h ib ito r  of catecholamine inactiva tion by 
competing fo r  the methylation enzymes, catechol-0 -methyl 
transferase and s-adenosyl methionine (4) and prevent high levels 
of catecholamines by pru lecling the a c l iv i t y  of monoamineoxidase, 
an enzyme responsible fo r  the transformation of catecholamines to 
th e ir  inactive state (5 ,6). Plasma ascorbic acid has been shown
2to decrease s ig n i f ic a n t ly  fo llow ing an intravenous administration 
of epinephrine to humans (7).
I I .  REVIEW OF THE LITERATURE
A. Stress and Catecholamine Levels
The two catecholamines of in te rest in th is  study, 
epinephrine and norepinephrine, are released in response to 
numerous s t im u li.  Almost a l l  of the c ircu la t ing  epinephrine 
is secreted by adrenergic chromaffin ce lls  in the adrenal 
medulla, however, some evidence exists fo r  central 
epinephrine-producing neurons located in brain stem areas (8-
10). Norepinephrine enters the c ircu la to ry  system as a
[
neurotransmitter released by the sympathetic nervous system 
with a minor amount secreted by noradrenergic chromaffin ce lls  
in the adrenal medulla.
I t  is d i f f i c u l t  to f ind  published normal ranges, but 
basal plasma catecholamine levels have been established on 
fas t ing , supine normotensive subjects. Before the development 
of assays that were sensitive to the lower ranges of 
catecholamines, investigators assumed the basal levels to be 
zero or less than one. Even a fte r the advent of the more 
sensitive and spec if ic  methods, reported basal levels show a 
great deal of in te r and in tra-study v a r ia b i l i t y ,  especially 
those using f lu rom etr ic  or double isotope techniques. As th is  
study w i l l  use a single isotope assay, only basal data
3obtained by a comparable method w i l l  be discussed. Basal 
levels from various sources are shown in Table I .
TABLE I
REPORTED BASAL CATECHOLAMINE LEVELS (pg/ml)
Study X(±SEM)NE X(±SEM)E
Cryer, et al (11) 227(±23) 44(±4)
Peuler and Johnson (12) 213(±21) 28(±6)
Cryer and Weiss (13) 182(±21) 44(±11)
Weise and Kopin (14) 208(±17) 67(±9)
Johnson, et al (15) 165(±12) 16(±2)
The lower levels in the las t study might be due to the 
sophistication of the subjects, who had partic ipated 
previously in s im ilar experiments. In a l l  of the studies 
discussed below, baseline, as opposed to basal levels, were 
established during the pre-treatment phase of the experiments 
and used fo r  comparison purposes.
The level of c ircu la t ing  catecholamines found at any 
given time is the resu lt  of physical, psychological and 
chemical influences. Gender, body position, physical and 
mental a c t iv i ty ,  and mood can a lte r  catecholamine secretion 
rates. Caffeine, n ico tine , and prescription or non­
prescription drugs can produce f luc tua t ing  levels (16). An 
increase in the secretion and excretion rate of catecholamines 
is  found a fte r exposure to a stressor. Catecholamine 
secretion is measured as e ither to ta l or separated
4(epinephrine, norepinephrine and dopamine) plasma 
catecholamines, while the excretion rate is usually determined 
on 24-hour urine samples. Total plasma catecholamine values 
provide no information as to the re la t ive  levels of 
epinephrine and norepinephrine, although i t  is commonly 
assumed tha t, a l l  other factors being equal, norepinephrine 
comprises 80% of the to ta l plasma catecholamines.
B. Stress and hypertension
The synergistic e f fec t of stress and catecholamine 
secretion has been implicated in the etio logy of hypertension. 
The data are equivocal as to whether E and NE act together or 
separately to produce and/or exacerbate hypertension. Genetic 
hypertensive rats (SHR's) show s ig n i f ic a n t ly  increased E and 
NE levels as compared to th e ir  normotensive controls (WKY's) 
fo llow ing cage trans fe r, footshock, and forced immobilization 
(17-19). An accelerated maturation of epinephrine secretion 
at f iv e  weeks of age in the Lyon hypertensive s tra in  has been 
reported with no apparent difference in secretion at twenty- 
one weeks of age (20).
Maudsley reactive rats had lower basal plasma 
norepinephrine levels than th e ir  normotensive contro ls, but no 
difference in basal epinephrine levels (21). Norepinephrine 
levels were negatively correlated with blood pressure and 
heart ra te , a f ind ing  explained as sympathetic compensation 
fo r  "other" influences.
The resu lts  obtained from studies of human hypertensives 
also are not d e f in i t iv e .  Elevated plasma catecholamine levels 
have been reported in human hypertensives and experimentally 
induced hypertensive rats (22). When separated catecholamines 
were assayed, higher baseline plasma epinephrine levels were 
present in human hypertensives as compared to normotensives, 
but norepinephrine levels were equivalent (23).
The stress of annoying disturbances during a monotonous 
task produced an increased epinephrine excretion in both 
hypertensives and normotensives (24). An increase in NE was 
noted only in normotensive females. There was no evidence 
that hypertensives have an exaggerated catecholamine response 
e ither at rest or under stress.
E lec tr ic  shock as a stressor
The administration of various in tens it ies  of e le c tr ic  
shock has proven extremely e ffec t ive  as a stressor. Total 
plasma catecholamines were measured in Sprague-Dawly rats 
before, during and at in te rva ls  fo r  f iv e  hours fo llow ing a 
protracted, high level of footshock stress (25). This level 
of shock resulted in f a ta l i t ie s  fo r  eleven of the nineteen 
experimental animals and produced plasma catecholamine levels 
s ig n i f ic a n t ly  elevated over baseline in the survivors and the 
le th a l i t ie s ,  with higher levels present in the le th a l i t ie s .
The survivors ' CA levels reached 150% over baseline a fte r 30 
minutes of stress and remained there throughout the post­
stress period. At th is  same po in t, CA levels in the rats tha t
did not survive had reached 280% over baseline and continued 
to r ise  u n t i l  death occurred. The a b i l i t y  to survive stress 
appears to be re lated not only to plasma CA leve ls, but also 
to the rate of increase and the time needed to return to 
baseline. This study would have provided more valuable 
information had epinephrine and norepinephrine been measured 
separately.
Studies that investigated separated catecholamines 
reported an increase in both epinephrine and norepinephrine 
fo llow ing footshock stress and transfer to the shock chamber 
(17,18). These resu lts  might have been confounded by 
obtaining blood samples immediately a fte r trans fe r, as 
catecholamine levels are known to be affected by the physical 
a c t iv i ty  produced by transfer from the home cage. The high NE 
levels might re f le c t  physical stress rather than fear or 
anxiety. Gentle handling of Sprague-Dawly rats produced a 
r ise  only in epinephrine levels, but immobilization resulted 
in an increase of both epinephrine and norepinephrine while 
decapitation produced an 80-fold increase in E levels and a 
10-fold increase in NE levels (26). Dopamine levels were 
undetectable under any condition. These resu lts  were 
confirmed in two la te r  studies (19,27).
Combined footshock and brain stimulation had an additive 
e f fe c t on norepinephrine levels but th e ir  e ffec t on 
epinephrine secretion was not greater than that caused by 
e ither stressor alone (28).
7Increased epinephrine excretion was found fo llow ing 
strong, but harmless levels of shock in humans (29) and, in a 
subsequent study, an tic ipation of shock produced a s ig n if ica n t  
r ise  in epinephrine excretion over levels obtained during a 
re laxation period (30). Norepinephrine excretion was not 
affected in e ither study.
D. Physical a c t iv i ty  as a stressor
Physical a c t iv i ty  has been used as a stressor in human 
studies. An early study measured the e ffec t of muscular work, 
ranging from moderate to heavy, on norepinephrine and 
epinephrine excretion rates (31). An increase in NE excretion 
over levels obtained during relaxation was noted, but 
epinephrine levels did not change from baseline.
A 6- fo ld  increase in norepinephrine excretion between 
pre and post-game levels occurred in professional hockey 
players (32). Only a moderate increase in epinephrine 
excretion was noted. No differences were found among amateur 
boxers, whose epinephrine levels were elevated in the pre­
match period and remained high a fte r the match. The authors 
concluded that high norepinephrine levels are associated with 
states of active aggression, while epinephrine levels increase 
under the condition of passive anxiety experienced by the 
amateur boxers who spent a great deal of time waiting to go on 
fo r  three minutes o f actual f ig h t  time.
A three-minute handgrip was used as stressor with blood 
samples taken before and during the handgrip (33). No
differences were found in plasma norepinephrine levels but 
epinephrine levels increased s ig n i f ic a n t ly  in the exercising 
arm. In subjects who had continuously climbed s ta irs  fo r  a 
to ta l of four minutes, both plasma epinephrine and 
norepinephrine levels increased over baseline (34). These 
contradictory find ings might re f le c t  the fac t that 
norepinephrine does not appear at peak levels in the blood 
stream u n t i l  four minutes a fter release, while epinephrine 
peaks at three minutes.
Some support fo r  the re la tionsh ip  of norepinephrine and 
physical stress was provided by a study that measured the 
urinary excretion of norepinephrine and epinephrine in 
th ir teen members of an amateur so ftba ll team during the las t 
seven games of the season (35). Results showed no s ig n if ican t 
differences in epinephrine excretion but a s ig n if ica n t group 
e f fe c t  was found fo r  norepinephrine, with the less sk i l le d  
players excreting a higher amount. The studies that attempt 
to look at the effects of physical stress cannot control fo r  
the confounding effects  of whatever psychological stress might 
be present.
Psychological stress
Real l i f e  s itua tions that involve considerable 
psychological stress have provided a convenient model to 
investigate the e ffec t of stress on catecholamine levels. 
Urinary excretion rates of norepinephrine and epinephrine were 
measured in paratroop trainees during night res t,  ground
9tra in in g  and during 2-3 hour jump sessions (36). Epinephrine 
excretion was s ig n i f ic a n t ly  increased during the jumping 
period over the ground a c t iv i ty  leve l. Norepinephrine levels 
were elevated only during the s ix th  and eighth jump. Both E 
and NE levels were increased s ig n i f ic a n t ly  over baseline 
during surface attack tra in in g  in A-10 p i lo ts  (37). The 
increase in NE might be due to the physical a c t iv i ty  involved 
in f l i g h t  manuevers, while the previously cited study 
controlled fo r  th is  by taking usual ground a c t iv i ty  as the 
baseline measure.
Plasma levels of epinephrine and norepinephrine were 
assayed before and a fte r students took the State Examination 
fo r  in terna l medicine at a medical school in Russia (38).
Both plasma epinephrine and norepinephrine were elevated a fte r 
the examination when compared to pre-examination values.
In s im i l ia r  studies, a compulsory, 6-hour matricu lation 
examination was used as the stress condition (39,40). 
Epinephrine excretion increased fo r  both males and females 
under the stress condition, but norepinephrine increased only 
in males. None of the studies reported whether the students 
remained seated or were allowed to move around.
Epinephrine and norepinephrine excretion levels were 
examined as a function of mental stress which ranged from 
working under d is trac t ing  conditions to mild punishment (41- 
43). A ll  of the studies reported a s ig n i f ic a n t ly  higher level 
of epinephrine excretion over baseline under the mental stress
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conditions. Changes in norepinephrine excretion levels were 
less marked.
An increase in epinephrine excretion was found in female 
subjects a fte r watching a disturbing movie when compared to 
excretion rates measured a fte r viewing a boring trave l f i lm  
(44). No change in norepinephrine levels occurred. Both NE 
and E levels increased s ig n i f ic a n t ly  a fte r watching a comedy 
f i lm  and a p a r t ic u la r ly  grusome ghost story.
Two studies used public speaking as the stress 
condition. One study obtained subjects who were scheduled to 
speak in a varie ty  of s ituations (45) and the other used young 
physicians who were presenting at medical conferences (34).
Both studies looked at plasma epinephrine and norepinephrine 
levels with a baseline value taken d ire c t ly  p r io r  to speaking, 
however one study collected the f in a l sample a fte r the speech 
was completed (45), while the other obtained the stress sample 
w ith in  the f i r s t  three minutes of speaking (34). A 
s ig n if ica n t increase was reported only in plasma 
norepinephrine levels a fte r speaking when sampling time was 
variab le. Opposite resu lts  were found when samples were 
obtained a fte r three minutes. A s ig n i f ic a n t ly  higher level of 
epinephrine was found, with no change noted fo r  norepinephrine 
leve ls. A follow-up study measured catecholamine response 
during the in i t i a l  moments of public speaking and again at 15 
minutes into the speech (46). Epinephrine levels were 
s ig n i f ic a n t ly  elevated over baseline at three minutes but had
approached baseline at 15 minutes. Norepinephrine increased 
at three minutes and remained high at the second sampling.
Both catecholamines respond to stress but epinephrine shows a 
dramatic increase in secretion that disappears rap id ly  from 
the c ircu la t io n ; norepinephrine appears to remain in the blood 
stream fo r a longer period.
Nicotine as a stressor
The evidence that n icotine d ire c t ly  stimulates the 
adrenal medulla has been well documented. Epinephrine 
excretion increased fo llow ing a period of heavy smoking but no 
comparable r ise  was seen fo r  norepinephrine excretion (47). 
These resu lts  were confirmed by two d if fe re n t assay 
techniques. The intravenous administration of n icotine 
produces a high level of blood epinephrine, exceeded only by 
the intravenuous administration of epinephrine (48,49).
The e ffec t of n icotine on epinephrine secretion was 
demonstrated in dogs who had inhaled cigarette smoke fo r an 
average of 3.5 minutes (50). Inhalation of corns ilk  c igare tte  
smoke was used as control and no s ig n if ica n t change over 
baseline was noted. Epinephrine levels in blood obtained from 
the adrenal vein, vena cava and femoral artery a l l  increased 
a fte r inhalation of c igare tte  smoke.
Epinephrine excretion in smokers was s ig n i f ic a n t ly  
higher than nonsmokers, but no differences were found in 
norepinephrine excretion levels (51). These resu lts  were 
replicated in a la te r study (52).
S ign ifican t increases in both plasma epinephrine and 
norepinephrine levels occurred a fte r subjects had smoked two 
non -f i l te red  cigarettes (53). Contradictory resu lts  were 
reported by a study tha t found a s ig n if ica n t  decrease in 
norepinephrine excretion when subjects stopped smoking but no 
corresponding decrease in epinephrine excretion (54).
Ascorbic acid levels and adrenal a lte ra tion  were 
investigated in guinea pigs who had inhaled c igarette smoke 
fo r  a period of up to twenty-one days (55). Ascorbic acid 
concentration in the adrenals was s ig n i f ic a n t ly  lower in the 
animals receiving the smoke and, a fte r 18 days, marked adrenal 
hypertrophy was noted.
Nicotine and ascorbic acid levels
A va r ie ty  of factors other than d ie tary intake can 
influence ascorbic acid status in man. These influences are 
re flected in changing ascorbic acid levels in plasma, whole 
blood, serum or leukocyte samples. Some factors which can 
a ffec t ascorbic acid levels are sex, age and smoking habits. 
Evidence w i l l  be presented below which discusses the influence 
of each of these variables, but the emphasis w i l l  be on 
studies which investigated the e ffec t of n icotine on ascorbic 
acid levels.
An early  investigation of the effects of vitamin C on 
tox ic  substances reported that 25 mg of the body's ascorbic 
acid was used to neutra lize the amount of n icotine contained 
in one cigarette  (56), and i t  has been shown that cigarette
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smoke destroys vitamin C in solution (57). A comparison of 
plasma and leucocyte ascorbic acid levels revealed that 
smokers had lower ascorbic acid levels than nonsmokers in both 
measures and those smokers who smoked more than 14 cigarettes 
per day had lower plasma levels than those who smoked less 
than 14 per day (57).
Ascorbic acid status was measured in 4600 subjects who 
had previously partic ipated in the N utr it ion  Canada National 
Survey (58). Median serum ascorbic acid levels were found to 
be 40% lower fo r  indiv iduals who smoked more than 20 
cigarettes per day. Intake of d ie tary vitamin C was 
contro lled fo r by grouping subjects according to information 
obtained from a 24-hour d ie tary re c a l l .  Median serum ascorbic 
acid levels increased as d ie tary  intake increased, but smokers 
were consistently lower at each range of intake. Median serum 
levels were higher in females than males and female smokers 
had consistently lower values than female nonsmokers.
A comparison of male smokers and nonsmokers found 
s ig n i f ic a n t ly  lower baseline whole blood and plasma levels of 
ascorbic acid in smokers (59). During the en tire  experiment, 
a l l  subjects were on a vitamin C res tr ic ted  d ie t .  A fter 
saturation with 2 g ascorbic acid fo r  f iv e  days, plasma and 
whole blood ascorbic acid levels were identica l in both 
groups. Measurement of urinary excretion of ascorbic acid 
p r io r  to and a fte r saturation revealed that smokers excreted 
ha lf the amount excreted by nonsmokers.
14
A rep lica t ion  of th is  experiment (60) produced s im i l ia r  
resu lts . No s ig n if ica n t differences were noted fo r  age, 
weight, consumption of coffee, tea or alcohol, and d ie tary  
intake. Baseline whole blood ascorbic acid levels were 30% 
lower in smokers. Following a 1.1 g ascorbic acid load, 
urinary excretion a fte r eight hours was s ig n i f ic a n t ly  less fo r 
the smokers, indicating a greater re tention. Subjects were 
saturated by receiving 1.1 g ascorbic acid fo r  f iv e  days and 
by removal of a l l  d ie tary re s t r ic t io n s .  Desaturation was 
accomplished by resuming intake re s tr ic t io n s  and discontinuing 
the supplements fo r  f iv e  days. F in a lly ,  two loading doses of 
1.1 g ascorbic acid were given on the las t day of the 
experiment. After saturation and desaturation, there was no 
s ig n if ica n t difference in whole blood ascorbic acid levels 
between the smokers and nonsmokers. Comparison of urinary 
excretion a fter the load on Day 1 and on the las t day of the 
experiment indicated that the smokers retained s ig n i f ic a n t ly  
more ascorbic acid. The author speculates that less ascorbic 
acid is available fo r  use by smokers or that smokers u t i l iz e  
ascorbic acid d i f fe re n t ly  than nonsmokers.
Plasma and leukocyte ascorbic acid levels were measured 
in subjects s t ra t i f ie d  by age, sex and number of cigarettes 
smoked (61). Among nonsmokers, there was a decrease in plasma 
ascorbic acid concentration with increasing age and a higher 
concentration in women of a l l  ages. Plasma ascorbic acid 
levels were lower in smokers than nonsmokers fo r both males
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and females. Because of the age related decrease in 
nonsmokers, the plasma ascorbic acid values fo r  smokers and 
nonsmokers are s im ilar at age 60 fo r  both males and females. 
There was no change in leukocyte ascorbic acid concentration 
with age* but women had higher concentrations than men. Both 
male and female smokers had reduced values as compared to non 
smokers. The authors state that heavy smoking has the same 
e ffec t on plasma ascorbic acid levels as the addition of 40 
chronological years.
Similar resu lts  were reported fo r  a population of 300 
indiv iduals older than 65 (62). There was also a s ig n if ica n t 
male-female d ifference, with females showing consistently  
higher values. Older smokers had lower levels than nonsmokers 
of the same age but th is  difference was not s ig n if ica n t when 
the amount of fresh f r u i t  consumed was considered. The 
corre la tion between ascorbic acid levels and f r u i t  intake was 
greater than the re la tionsh ip  between blood ascorbic acid 
levels and smoking, perhaps ind icating that intake can 
compensate fo r  the deleterious e ffec t of smoking on ascorbic 
acid leve ls. Other studies have reported s im ila r resu lts  fo r 
age and sex (63-67).
Two related studies used a k ine t ic  approach to 
investigate the d is tr ib u t io n  ra te , metabolism, body pool size 
and excretion of ascorbic acid in male nonsmokers and smokers 
who used more than 20 cigarettes per day (66,67). To achieve 
a steady state condition, subjects followed an ascorbic acid
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de fic ien t d ie t during a three week equ il ib ra t ion  period and 
during the two week experimental period while taking an oral 
dose of ascorbic acid which ranged from 30 to 180 mg/day. At 
the beginning of the two week experimental period, one dose of 
I ascorbic acid was administered. Washout of the 
remaining ra d io a c t iv i ty  was accomplished by ingesting 
megadoses of ascorbate (8 x 500 mg/day) fo r  eight days.
Steady state concentration of plasma ascorbic acid, to ta l 
turnover (mg/day), metabolic turnover (mg/day) and body pool 
(mg/kg body weight) were calculated fo r  both groups. Results 
indicate that smokers require s ig n i f ic a n t ly  higher to ta l 
turnovers to achieve plasma levels and body pools comparable 
to nonsmokers. Smokers have a higher metabolic turnover than 
nonsmokers at corresponding steady state concentrations (70-90 
mg/day versus 40-50 mg/day). Based on these find ings, the 
authors recommend that non smokers require an intake of 100 
mg/day and smokers 140 mg/day.
A p i lo t  study (Smith, 1981) conducted in th is  laboratory 
has confirmed that smokers have s ig n i f ic a n t ly  lower ascorbic 
acid levels than nonsmokers of comparable age and d ie tary 
intake. Biochemical determinations were done on whole blood, 
serum and leukocyte samples. The resu lts  showed that smokers 
have s ig n i f ic a n t ly  lower ascorbic acid levels irrespective of 
the method used.
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I I I .  HYPOTHESES
I t  has been well established that an increase in 
catecholamine secretion occurs concomitantly with stress. The 
co n f l ic t in g  resu lts  as to which catecholamine is affected by 
psychological as opposed to physical stress are most probably due 
to experimental designs that confound these variables and that do 
not control fo r  time of appearance and the short h a lf - l iv e s  of 
catecholamines in the c ircu la to ry  system. The most accurate 
information on the e ffec t of psychological stress would appear to 
be that obtained from fasting  subjects who had been s i t t in g  , 
qu ie t ly  fo r  over 30 minutes, with blood samples drawn three to 
four minutes a fte r the onset of psychological stress. Public 
speaking has been shown to be an e ffec t ive  psychological stressor 
that involves a minimum of physical a c t iv i ty .
I t  has also been well documented that nicotine is a chemical 
stressor that d ire c t ly  stimulates the adrenal medulla and depletes 
plasma ascorbic acid, e ither d ire c t ly  or as a resu lt  of increased 
catecholamine levels. There is  some evidence that other types of 
stress w i l l  cause a decrease in plasma ascorbic acid levels.
Because of the strong evidence re la t ing  psychological stress 
and n icotine to catecholamine levels and the weaker evidence 
implicating a depletion of blood ascorbic acid and a simultaneous 
increase in catecholamine levels as a resu lt  of stress, th is  study 
has the fo llow ing hypotheses:
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1. Smokers w i l l  have higher i n i t i a l  c ircu la t in g  
catecholamine levels and lower plasma ascorbic acid levels than 
nonsmokers.
2. Smokers taking an ascorbic acid supplement w i l l  have 
lower catecholamine levels during a pre-stress measurement than 
smokers taking placebo.
3. Both smokers and nonsmokers w i l l  show an increase in 
c ircu la t ing  catecholamines fo llow ing the stress period.
4. The catecholamine most affected by psychological stress 
w i l l  be epinephrine.
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IV. METHODS
A. Materials
Subjects The subjects consisted of 30 smokers and 13 
non-smokers who met the fo llow ing c r i te r ia :
1. Because of age and sex differences in ascorbic acid 
levels and catecholamine response, subjects were lim ited  to 
healthy males between the ages of 18-45.
2. Subjects passed a physical exam designed to detect 
c l in ic a l  signs of vitamin C deficiency.
3. Nonsmokers had never smoked or had abstained from 
smoking fo r  at least one year.
4. Smokers had consumed at least 20 cigarettes/day fo r  
the las t year.
5. Only smokers who had no desire to stop smoking or 
to decrease th e ir  present rate of consumption at the time of 
the study were accepted.
6 . Subjects were not taking any prescription 
medications.
7. Users of drugs which have an e ffec t on the 
secretion rate and/or serum level of ascorbic acid and 
catecholamines were excluded from the study.
8 . Vitamin C supplements had not been used on a 
regular basis fo r  at least three months previous to the study.
The subjects were recru ited by advertisement from the 
University of Nebraska Medical Center, the University of
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Nebraska at Omaha* and, when response from these sources was 
not adequate, from the general public .
Smokers were paid $200.00 fo r th e ir  pa rt ic ipa tion  in the 
study and nonsmokers received $150.00. A ll subjects had to 
complete the en tire  experiment to be e l ig ib le  fo r  payment*
Dietary and smoking information A ll subjects were 
provided with a d ie tary record form which covered two randomly 
selected days of each week. In addition, smokers were 
required to complete a smoking record form fo r  the same two 
randomly selected days.
The d ie tary record form provided information on the 
adequacy of the subjects' d iets and detected any dramatic 
changes in the consumption of foods containing high levels of 
ascorbic acid.
Stress Psychological stress and the resu lt ing  anxiety 
were produced during a three-hour session where the subjects 
randomly chose three jokes which they were instructed to 
memorize. Prior to the stress te s t ,  the jokes were collected. 
Subjects then delivered th e ir  jokes during a three-minute 
period and the other subjects rated th e ir  presentation on a 
scale of 0 to 20. A fter a l l  subjects had partic ipated , the 
subject with the highest score was awarded a $25.00 prize.
Baseline and pre-stress plasma catecholamine levels were 
measured a fte r a l l  subjects had been seated qu ie tly  fo r at 
least 30 minutes and before being to ld  the de ta ils  of the 
stress te s t .  The stress sample was obtained at the end of the
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three-minute presentation period as the subject was f in ish in g  
with his th ird  joke.
P ro f i le  of Mood States (POMS) An additional measure 
of anxiety was provided by the administration of the tension- 
anxiety (T) scale from the POMS test*
The T-scale is composed of a 5-point adjective ra ting  
scale with which the subject indicates how closely they 
describe his fee lings. A zero indicates 'not at a l l '  while a 
4 indicates 'extremely.' The T-scale is self-administered and 
can be completed in f iv e  minutes.
Studies with patient normative samples show the POMS to 
be in te rn a l ly  consistent and to have a sa tis fac to ry  te s t-  
re test r e l i a b i l i t y .  Content, predictive and concurrent 
v a l id i t y  were established on normal college students, 
psych ia tr ic  outpatients and male VA outpatients. Tension- 
anxiety scores correlated .80 with the Taylor Manifest Anxiety 
Scale, decreased in patients a fter treatment with Librium when 
compared to placebo and showed a concurrent increase with 
palmar sweating during a stress condition (68).
The POMS was given during the pre-treatment baseline 
period and again during the three-hour stress session.
B. Design
1. Groups Smokers were randomly assigned to e ither the
treatment or control group. The treatment group ingested 
500 mg of vitamin C once each day while the control group 
was given an identica l placebo. Nonsmokers received
placebos only. A ll subjects reported once each week on a 
preassigned day to turn in th e ir  smoking and/or d ie tary 
record forms and to pick up th e ir  next week's supply of 
forms and supplements.
2. Experimental schedule The experiment covered a to ta l of 
f iv e  weeks. This was broken down as fo llows:
a. A one-week pre-treatment period. Subjects followed 
th e ir  regular diets and took no supplements.
b. A four-week treatment period where subjects ingested 
th e ir  supplements or placebos.
Procedures
The procedures fo r the five-week experimental period 
were as outlined below:
1. One-week pre-treatment period A ll subjects reported at 
the end of the f i r s t  week fo r a three-hour session 
(beginning at 7:00 A.M.).
a. POMS (Mood Scale) was administered.
b. A fte r s i t t in g  qu ie tly  fo r  30 minutes* ten ml of blood 
was drawn fo r  baseline plasma ascorbic acid and plasma 
catecholamine levels.
c. Subjects were given a smoking and/or d ie tary record 
fo r  the fo llow ing week. The f i r s t  completed records were 
collected.
d. Each subject was given a week's supply of supplement 
or placebo.
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2. Four-week treatment period The procedure fo r  the f i r s t  
three weeks was as fo llows:
a. Subjects reported once a week fo r  blood draw to 
determine ascorbic acid levels (smokers on ly).
b. Subjects turned in th e ir  smoking and/or d ietary 
records and received next week's forms.
c. Supplement boxes were returned and new supplements 
d is tr ibu te d .
d. The number of tab lets remaining were counted as an 
estimation of compliance.
3. Fourth-week At the end of the fourth week, the fo llow ing 
measures were repeated at a three-hour stress session:
a. POMS
b. Blood fo r  plasma catecholamine and plasma ascorbic 
acid levels (2 X, once before speaking and during 
speaking).
c. Number of c igarettes smoked during the session.
d. Smoking and/or d ie tary records and supplements were 
returned.
e. Stress tes t
D. S ta t is t ic a l Analyses
A ll data were analyzed with SPSS procedures available 
through the University of Nebraska Medical Center's 
In te ractive  t1me-shar1ng system. P robab ility  level fo r 
re jec ting  the nu ll hypotheses was established at p<.05 (two- 
ta i le d )  .
Baseline (pre-treatment) plasma epinephrine and 
norepinephrine and plasma ascorbic acid levels of smokers and 
nonsmokers were compared by Student's t - te s t  fo r differences 
between groups to v e r i fy  the hypothesized i n i t i a l  differences.
Plasma ascorbic acid levels of smokers taking vitamin C 
supplements and smokers taking placebo were analyzed by 
repeated measures beginning one week a fter s ta rt ing  treatment 
to confirm that smokers on vitamin C supplements had reached 
saturation levels and that plasma C levels of smokers on 
placebo remained low.
The e ffects  of stress and treatment on epinephrine and 
norepinephrine levels were analyzed by a two-way ANOVA, NE and 
E X condition (baseline, pre-stress, during stress) X group 
(smokers on C9 smokers on placebo, nonsmokers).
BIOCHEMICAL ASSAYS
A. Radioenzymatic Assay fo r  Catecholamines
The radioenzymatic assay fo r  the determination o f 
plasma catecholamines is based on the single isotope method 
developed by Passon and Peuler (69). The enzyme, catechol-0- 
methyl-transferase (COMT), is  used to catalyze the transfer of 
a ^H-methyl group from S-adenosyl-L-methionine, (^H- 
methyl) (^H-SAM) to norepinephrine and epinephrine. The 
resu lt ing  products, ^H-normetanephrine and ^H-metanephrine are 
extracted arid isolated by th in  layer chromatography and 
counted by l iq u id  s c in t i l la t io n .
Thin layer chromatography (TLC) The separation of the 
labeled norepinephrine and epinephrine by TLC depends on two 
phases. The stationary phase is formed by the adherence of a 
th in  layer of s i l ic a  gel sprayed onto a glass p la te. After 
the samples have been applied as spots, the plate is placed 
v e r t ic a l ly  in a chamber containing the mobile phase (solvent). 
The solvent ascends through the layer by ca p i l la ry  migration. 
Sample substances are detected by viewing under a UV l ig h t  
a fte r the mobile phase has been removed and the plate dried. 
The dried samples are scraped from the plate in to the 
appropriate s c in t i l la t io n  v ia ls .  TLC was developed in 1938 by 
Izmailon and Schraiber (70).
Liquid s c in t i l la t io n  counting Liquid s c in t i l la t io n  
derives i t s  name from the l iq u id  mixture of sample, solvent 
and f lu o r .  The labeled epinephrine and norepinephrine emit 
low levels of beta rad ia tion that cannot be measured by solid  
s c in t i l la t io n  counting. For th is  study, toluene was used as 
solvent and L iq u if lu o r  as the f lu o r .  Fluors are complex 
heterocyclic, organic compounds which, when excited, emit 
photons in the near u l t ra v io le t  range. The sample emissions 
f i r s t  excite the solvent molecules, which in turn excite the 
f lu o r  electrons to emit photons as they return to the ground 
state. Paired photomultip lier tubes are u t i l iz e d  to detect 
the photons and resu lt  1n e le c tr ic a l pulses which are passed 
through a coincidence c i r c u i t  and e le c tro n ica lly  summed (71).
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Sample preparation
- Blood samples must be collected in special evacuated tubes 
containing EGTA and glutathione, which have been added to the 
tubes in a solution (pH 6 .0-7.4) containing 90 mg/ml EGTA and 
60 mg/ml glutathione* Twenty m ic ro lite rs  of the solution was 
needed fo r  each ml of blood.
- After co l le c tion , the tube is inverted several times, but 
not shaken, to mix the blood with preservatives.
- Samples must be placed immediately in an ice bath and 
centrifuged in a re fr igera ted  centrifuge as soon as possible.
- A fter separation of the plasma, samples can be frozen and 
are stable fo r  at least three months when stored in a t ig h t ly  
closed container at temperatures below -20°C.
Procedure
1. Thawed samples must be centrifuged i f  the plasma is not 
c lear.
2. The fo llow ing 13 X 100 mm tubes are labeled and placed in 
an ice bath: Blank (X 2), control (X 2), control+standard 
(X 2), sample unknown (X 2), sample+standard (X 2). Each 
sample is analyzed in duplicate.
3. 50 pi of each sample is added to the sample tube and the
sample+std tube.
4. 50 pi of each control is added to the control and
control+std tubes.
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5. 50 pi of the sample vehicle is added to the blank tubes.
( I f  samples are analyzed in d if fe re n t vehicles, a separate 
blank must be run fo r  each).
6 . 10 pi of d ilu ted s ta b i l iz in g  solution (1 to 10,000 with 
d is t i l le d  H2O) is added to the con tro l, sample and blank 
tubes.
7. 10 pi of d ilu ted catecholamine standard solution (1 to 
10,000 with d is t i l le d  H2O) is added to the control+std and 
sample+std tubes in a concentration equal to 100 pg/sample 
tube.
8 . The reagent mixture is prepared in a disposable tube in 
the fo llow ing proportions:
D is t i l le d  water 10 pi
Buffer solution 10 pi
3H-SAM 10 ill
C0MT enzyme solution 10 pi
The mixture is vortexed l ig h t ly  before and a fte r additon
of COMT. Because SAM is very ac id ic , the enzyme should 
not be layered on the acid as th is  causes denaturation.
9. 40 pi of the reagent mixture is added to each tube.
10. The tubes are vortexed gently and centrifuged b r ie f ly  at
300 X g fo r  30 seconds (1500 rpm fo r  Beckman J21B).
11. A ll tubes are incubated at 37^c fo r 60 minutes in a
shaking water bath. The tubes are then placed in an ice
bath.
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12. 50 pi of stopping solution is added and the tubes are 
vortexed vigorously.
13. A second set of 13 X 100 mm glass tubes is  labeled.
14. 0.1 ml of 0.1 M acetic acid is added to each.
15. 2 ml of toluene/amyl alcohol (3:2, v/v) is  added to the 
incubation tubes and vortexed vigorously. After 
centrifug ing at 800 X g fo r  2 minutes, each tube is quick 
frozen (15 seconds) in a dry ice alcohol bath.
16. The tubes are removed from the bath and blotted to remove 
alcohol. The organic phase is decanted into the second 
set of tubes and the lower aqueous phase is discarded.
17. A fter vortexing vigorously, the tubes are centrifuged at 
800 X g fo r  2 minutes and quick frozen in a dry ice 
alcohol bath. The upper layer is aspirated o f f  and 
discarded.
18. Stopping point: stopper tubes and store at -20°C.
19. 0.1 to 0.15 ml absolute ethanol is added to the thawed 
acetic acid to f a c i l i t a t e  evaporation. Vortex u n t i l  a 
clear solution resu lts  and centrifuge at 800 X g fo r  1 
minute.
20. Label channels on th in  layer chromatography p late, 
om itting the outer lanes. The acetic acid/ethanol mixture 
is applied as a single spot 2 cm from bottom of p late. A 
warm a ir  stream w i l l  aid evaporation.
21. The plates are placed in a paper lined developing tank.
The solvent should be no less than 1 cm below the spots.
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Develop with te r t ia ry  amyl alcohol/benzene/methylamine 
(6:2:3, v /v /v ) .  Solvent prepared immediately before use 
produces the best separation. The solvent is permitted to 
migrate to the top of the plate.
22. The plates are removed from the tank and a ir  dried* The 
developing solvent is discarded. The plates are placed 
under a 254 nm l ig h t  and the zones are marked as fo llows:
Top - 3 methoxytyramine - dopamine 
Middle - Metanephrine - epinephrine 
Bottom - Normetanephrine - norepinephrine 
The zones are outlined with a sharp object WITHOUT 
TOUCHING THE ZONES.
23. Stopping point - i f  longer than overnight place the plates 
in a dessicator.
24. One s c in t i l la t io n  v ia l is labeled fo r  each catecholamine.
25. TLC plates are separated into sections at the prescored 
lines . The s i l ic a  gel is ca re fu lly  scraped from each zone 
in to the appropriate v ia l .
26. Stopping point ( i f  desired).
27. 1 ml of 0.05 ammonium hydroxide is added to the 
s c in t i l la t io n  v ia ls  containing the s i l ic a  gel from the 
Middle zone (A-epinephrine) and the Bottom zone (B- 
norepinephrine) and vortexed to extract the amine from the 
s i 1 ica.
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28. Periodate Oxidation Step - 50 pi of sodium metaperiodate 
solution is added at timed in te rva ls  to both A and B v ia ls  
and mixed vigorously.
29. A fter 5 minutes, 50 pi of glycerol solution is added to 
each v ia l (A and B). Maintain time in te rva l*
30. 1 ml of 0.1 M acetic acid is added to each v ia l (A and B) 
and vortexed to neutra lize the reaction.
31. 10 ml of to luene/L iqu if luo r (1000:50, v/v) is added to 
each v ia l ,  using adequate ve n t i la t io n .
32. The v ia ls  are capped and shaken vigorously. The v ia ls  are 
dark controlled and counted in a Liquid S c in t i l la t io n  
Counter.
33. Vial A contains ra d io a c t iv i ty  from epinephrine. Vial B 
contains ra d io a c t iv i ty  from norephinephrine.
Precautions
Standards - The assay is linear to 3000 pg/sample fo r  NE and
E. The amount of standard added to the sample may be adjusted 
to be compatible to the quantity found in the sample. Further 
d i lu t ion s  with s ta b i l iz in g  solution or d is t i l le d  water is more 
acceptable than increasing the standards. Samples can be 
d ilu ted with s ta b i l iz in g  solution i f  the concentration is 
greater than 3000 pg.
Radioactive counting
- Instrument background is included in the assay blank and is 
automatically subtracted by the l iq u id  s c in t i l la t io n  counter.
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Inh ib it io n  of Q-methylation
- Some plasma samples may in h ib i t  O-methylation of 
catecholamines. The amount of ra d io a c t iv i ty  a ttr ibu ted  to 
added standard is not as high as expected.
B. Oxidation Spectrophotometric Assay fo r  Plasma Ascorbic Acid 
(DNPH Method).
There has been a re l ia b le  and precise assay fo r  plasma 
ascorbic acid levels available since 1945 (72) and the present 
method is  essen tia lly  unchanged.
Plasma ascorbic acid is oxidized to dehydroascorbic 
acid in the presense of copper ion. The addition of 2,4 
dinitrophenyl hydrazine (DNPH) forms bis 2,4- 
dinitrophenylhydrozone. This deriva tive , when dissolved in 
sulpheric acid, forms a red-orange product that absorbs at 520 
nm and can be measured spectrophotometrically.
Sample co llec tion  and handling.
- Blood samples are collected with EDTA as anticoagulent.
- Proteins are precip ita ted from the sample by the addition 
o f tr ich lo ro a ce tic  acid (10 g/100 m l).
- A fter cen tr ifug ing , the pro te in-free f i l t r a t e  is decanted 
in to clean tubes and can be frozen at -20°C. The samples are 
stable at th is  temperature fo r  one month.
Procedure
1. Oxidation step
The color reagent, consisting of 2.2% 2,4 
dinitrophenylhydrazine, 5% thiourea and 0.6% CUSO4 , is
added to each tube. Thiourea prevents the fu r the r 
oxidation of dehydroascorbic acid.
The tubes are incubated at 60°C fo r  one hour.
2. Color development
After incubation, the tubes are ch il le d  in an ice 
bath and slowly, by drops, 2.5 ml of cold 65% su lfu r ic  
acid is added to each tube and mixed we ll.
The tubes must be kept well ch i l le d  or destruction 
of the sample w i l l  re su lt .
Sample tubes are removed from the ice bath and 
allowed to stand fo r  20 minutes at room temperature.
Other color products which can be read at the same 
wavelength are produced by th is  reaction. These 
in te r fe r in g  products are short lived and w i l l  degrade 
during the 20 minute standing period.
The tubes are read at 515 nm in a 
spectrophotometer.
Controls
No commercial controls are available as the ascorbic 
acid is destroyed by the production processes. A serum pool, 
with samples obtained monthly from normal subjects, is used as 
control and are run with each assay. A standard curve also is  
run with each assay.
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VI. RESULTS
A. Plasma Ascorbic Acid
As shown in Table I I ,  mean plasma ascorbic acid (PAA) 
concentration in the smokers was s ig n i f ic a n t ly  lower than the 
nonsmokers at the baseline measure ( F ( l , /l l ) “ 16*0/l ; pc.Ol)* 
Smokers assigned to the treatment group attained a 
s ig n i f ic a n t ly  higher than baseline level a fte r one week on 
vitamin C supplements and maintained these levels throughout 
the remainder of the treatment period (Repeated measures: 
F(5,13)=15.34; pc.O l). Mean PAA levels of smokers in the 
placebo group did not change over time from baseline (Repeated 
measures: F(5,15)=2.12; p>.05) and were s ig n i f ic a n t ly  lower 
than nonsmokers at a l l  measures (Student's t  values >4.00; 
pc .O l).
Group comparisons between treatment and placebo smokers 
showed tha t mean PAA was s ig n i f ic a n t ly  higher in the treatment 
group a fter one week and remained higher at the four 
successive sampling times (a l l  t  values >6.00; pc.O l). 
Comparison with the two subsequent measures in the nonsmoking 
group indicates tha t mean PAA levels in smokers assigned to 
the treatment group surpassed the nonsmokers at both times ( t  
values >2.2; pc.05).
Mean PAA in nonsmokers did not change over time from 
baseline (Repeated measures: F(2,26)=2.00; p>.15).
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B. Plasma Catecholamine Levels
Analysis of variance indicated that vitamin C 
supplements had no e ffec t on e ither E (F(1,123)=.31; p>.50) or 
NE (F(1,123)=1.89; p>.10). Pearson corre lations between PAA 
and both E and NE values were not s ig n if ica n t at any condition 
( r 's  <.32; p>.05). Because PAA was not related to 
catecholamine leve ls , treatment and placebo smokers were 
combined fo r  analysis of stress e ffec ts .
Mean plasma E and NE values fo r  smokers and nonsmokers 
are shown in Table I I I .  An analysis of variance of 
catecholamine levels by group (smoker or nonsmoker) with 
repeated measures on conditions (baseline, pre-stress, and 
stress) showed that there were no differences between groups 
fo r  e ither plasma E (F(l,41)=.14; p>.50) or NE (F(1,41)=1.19; 
p>.25). A s ig n if ica n t condition e ffec t was present fo r  both E 
(F(2,41)=31.6; p<.01) and NE (F(2,41)=5.3; p<.01). Within 
group repeated measures indicated that mean plasma E levels 
increased s ig n i f ic a n t ly  during the stress condition in both 
smokers (F(2,58)=23.8; p<.01) and nonsmokers (F(2,24)=10.6; 
p<.01). Mean plasma NE levels in smokers at pre-stress and 
stress conditions did not change from baseline (F(2,58)=1.59; 
p>.20). A s ig n if ica n t increase in mean plasma NE occurred in 
the nonsmokers during stress (F(2,24)=11.0; p<.01).
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C. POMS
Pearson corre la tions between anxiety scores and plasma E 
and NE levels were not s ig n if ica n t  (a l l  r 's  <.40; p>.05). The 
smoker's mean anxiety score at baseline was s ig n i f ic a n t ly  
higher then the nonsmokers (9.76±5.5 versus 6.3±3.12: t=2.46; 
p<.05). This difference was not present during the stress 
session (8.4±4.9 versus 6.4±2.4: t=1.62; p>.10).
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V II. DISCUSSION
Ascorbic acid, by i t s  ro le  in th e ir  production and 
metabolism, appears to be involved in the regulation of 
catecholamine levels (1-6). I t  was predicted that PAA levels 
would be re lated to plasma E and NE measures. This would be 
p a r t ic u la r ly  evident in smokers who have lower PAA levels due to 
the destructive e ffec t of n ico tine . This hypothesis was not 
substantiated. Ingestion of vitamin C supplements had no e ffec t 
on E or NE levels and corre la tions indicate that there was no 
re la t ionsh ip  between PAA and NE or E values. Previous studies 
have shown a lte ra tions of tissue catecholamine levels related to 
ascorbic acid supplementation or deficiency (73,74). More recent 
investigations in rodent and human subjects fa i le d  to support 
these resu lts . Dietary megadoses of ascorbic acid had no e ffec t 
on serum or tissue amine levels in ra ts  (75), and urinary 
excretion values in man did not change over a three-month period 
while ingesting 3.0 g/day ascorbic acid (76). However, an induced 
deficiency in guinea pigs produced decreased NE levels in 
cerebrum, cerebellum and midbrain a ttr ibu ted  to depressed a c t iv i ty  
of dopamine-j^-hydroxylase (77). I f  catecholamine levels are 
affected only under scorbutic conditions, th is  would account fo r  
the negative find ings in the present study. Physical examination 
of the subjects revealed no c l in ic a l  signs of ascorbic acid 
deficiency and PAA levels in smokers, while below those found in 
nonsmokers, were above the lower l im its  of normal. The study tha t 
reported changes in E and NE levels with supplementation
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administered ascorbate by in jec tion  (73). Both the form of the 
supplement and the route of administration d i f fe r  from the present 
study and the investigators did not measure plasma catecholamine 
levels (73,77). In the present study, oral vitamin C 
supplementation of 500 mg/day had no e ffec t on plasma 
catecholamine levels.
The POMS anxiety scores indicate tha t, as a group, smokers 
are more anxious than nonsmokers. This difference was present 
only at the i n i t i a l  measure. Mean anxiety scores obtained during 
the stress session show higher, but not s ig n i f ic a n t ly  d i f fe re n t,  
values in the smoking group. The decrease in the mean anxiety 
score in smokers at the time of the second measure might be due to 
a learning e ffec t from the f i r s t  tes t or a habituation to the 
experimental se tt ing .
The present f ind ing  that smokers and nonsmokers have 
comparable plasma E and NE levels is in disagreement with resu lts  
from previous studies (48,51-53). While the concensus regarding 
the e ffec t of smoking on NE is  fa r  from unanimous, most 
investigators have reported appreciably higher E levels in smokers 
fo llow ing a period of heavy smoking. They a t t r ib u te  th is  increase 
to adrenomedullary stimulation by n ico tine . Five studies examined 
urinary (47,48,51), serum (52) and plasma (53) E and NE levels in 
a series of smoking versus nonsmoking periods. A ll  of the studies 
found s ig n i f ic a n t ly  higher E levels during the smoking as compared 
to the nonsmoking segments. Only one of the studies reported a 
concomitant increase in NE levels fo llow ing smoking (53). Three
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studies measured urinary E and NE levels in groups of smokers and 
nonsmokers (47,52,78). Two of the studies found no difference in 
E or NE levels between smokers and nonsmokers (47,78) and one 
reported a higher E level in the smoking group (51). Elevated 
catecholamine levels under the a r t i f i c a l  conditions o f contro lled 
smoking and nonsmoking periods might be more representative of 
acute n icotine stress e ffec ts  than an accurate portrayal of the 
chronic e ffec ts  experienced by the habitual smoker. Results 
obtained from manipulated smoking behavior do not appear to be 
va lid  in r e a l - l i f e  applica tion. The present study shows that 
smokers and nonsmokers have comparable plasma E and NE levels, 
ind icating an adaptation in smokers to continual nicotine 
exposure. Adaptation has been shown experimentally to occur in 
ra ts  a fte r 14 days of chronic nicotine administration (79). 
S ign ifican t increases in the a c t iv i ty  of enzymes responsible fo r  
catecholamine metabolism, p a r t ic u la r ly  catechol-0-methyl- 
transferase (COMT), were concomitant with the return of amine 
levels to normal and remained elevated during the time nicotine 
stress was present (79).
S ign ifican t increases in plasma E levels were found in both 
smokers and nonsmokers during the stress condition. Several 
factors point to public speaking anxiety as the causal agent in 
these increases. To ensure that va lid  baseline data were 
availab le, two separate measures were obtained. An in i t i a l  
baseline was established at the f i r s t  session and a second, pre­
stress level was determined four weeks la te r .  Comparison with
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pre-stress levels showed no change from in i t i a l  E baseline fo r  
e ither smokers or nonsmokers. The dramatic r ise  in E over both 
the baseline and pre-stress measures appears to be due so le ly to 
the effects o f , the stress condition.
Sample timing has been shown to be a c r i t i c a l  variable in 
the accurate assessment of environmental stress e ffects  on 
c ircu la t in g  E concentrations (46). Epinephrine peaks and 
disappears rap id ly  from the c ircu la t io n  a fte r the i n i t i a l  onset of 
environmental stress conditions. Plasma levels obtained a fte r the 
f i r s t  three minutes would detect E as i t  descends toward normal.
The present study measured plasma catecholamines at three minutes 
a fte r  in i t ia t io n  of public speaking and should re f le c t  peak 
values.
While the resu lts  fo r  E are stra ightforward, the NE data do 
nothing to c la r i f y  the already confusing issue regarding i ts  
re la t ionsh ip  to stress. Mean NE levels in smokers did not change 
during the course of the experiment; however, the stress condition 
produced a s ig n if ica n t  increase in NE in the nonsmokers. These 
resu lts  are complicated fu r the r by group comparisons that indicate 
no difference in NE levels between smokers and nonsmokers. This 
might be explained, in part, by the large w ith in group variance 
and unequal group numbers. Although the difference was not 
s ig n i f ic a n t ,  mean NE levels in smokers were consistently higher 
than the nonsmokers at baseline and pre-stress measures. 
Norepinephrine values in smokers did not show an additional 
increase under the stress condition, but remained at th e ir
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previous high leve l. Mean NE values in nonsmokers increased 
during stress u n t i l  i t  reached a level almost identica l to that 
found in the smokers. The elevated mean NE in nonsmokers during 
stress also was s im ila r to that measured in smokers under 
nonstress conditions. The physiological implications of th is  arc 
important. Smokers exh ib it  NE concentrations in nonstress 
conditions tha t are comparable to those found in nonsmoking 
subjects during an environmental stress s itua t ion . I t  is as i f  
smokers were experiencing the e ffects  of a con tinua lly  applied 
environmental stress. Their NE levels are high and perhaps cannot 
increase even with an additional stressor.
In spite of the confusion surrounding the NE data, certa in 
conclusions can be drawn from the resu lts  of the present study. 
Smokers appear to be more anxious than nonsmokers as measured by 
th e ir  i n i t i a l  scores on the POMS. I t  is a matter fo r  speculation 
whether th is  is a re su lt  or a cause of smoking. C ircu la ting 
levels o f E and NE are affected by exposure to an environmental 
stress condition. The increase of NE appears to be masked in 
smokers, whose high nonstress levels are not add it iona lly  
increased with stress. Adaptation to chronic n icotine ingestion 
does not appear to occur as successfully with NE as with E. Mean 
epinephrine levels in smokers measured under nonstress conditions 
are as low, or lower, than those found in nonsmokers. Thus some 
mechanism exists to regulate c ircu la t in g  E in the presence of 
continual n icotine exposure.
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